Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29798960 | 0.98 | TDP1 (0.58) | MAOBTDP1L3MBTL1BCHEACHE | |
| SCHEMBL28696286 | 0.98 | TDP1 (0.58) | MAOBTDP1L3MBTL1BCHEACHE | |
| SCHEMBL30601913 | 0.98 | TDP1 (0.58) | MAOBTDP1L3MBTL1BCHEACHE | |
| SCHEMBL22777375 | 0.98 | TDP1 (0.58) | MAOBTDP1L3MBTL1BCHEACHE | |
| SCHEMBL30797187 | 0.95 | MAOB (0.55) | MAOBTDP1L3MBTL1BCHEACHE | |
| SCHEMBL314533 | 0.95 | MAOB (0.55) | MAOBTDP1L3MBTL1BCHEACHE | |
| SCHEMBL19429938 | 0.89 | MAOB (0.50) | MAOBTDP1L3MBTL1BCHEACHE | |
| SCHEMBL103036 | 0.87 | GLS (0.55) | MAOBTDP1L3MBTL1BCHEACHE | |
| SCHEMBL27891633 | 0.85 | HEXA (0.66) | MAPTRAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL6790333 | 0.84 | TDP1 (0.71) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | OMEICOS THERAPEUTICS GMBH (DE) | 2025-07-29 | — | — | US | disclosed |
| EP-4577526-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025129104-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-120051461-A | VHH antibody conjugates | 雅博得乐医疗公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| CN-119367342-A | CYP-eicosanoids analogs for treating or preventing diseases associated with neovascularization and/or inflammation | 奥迈科斯治疗公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-119325465-A | Biphenyl substituted epithelial sodium channel blocking compounds | 帕里昂科学公司 | 2025-01-17 | — | — | CN | disclosed |
| EP-4469441-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | Parion Sciences, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1648905-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | Abbott Laboratories (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-01-27 | — | — | US | disclosed |
| EP-0189307-B1 | ANTIHISTAMINE-H2 ALKYNE THIADIAZOLE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-08-29 | — | — | EP | disclosed |
| US-4732980-A | HISTAMINE H-2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-03-22 | — | — | US | disclosed |
| US-4663331-A | HISTAMINE H2-ANTAGONIST | SMITHKLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-05-05 | — | — | US | disclosed |
| EP-0189307-A2 | Antihistamine-H2 alkyne thiadiazole derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1G | MAOB 1287/4885TDP1 2766/4885L3MBTL1 2451/4885 |
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, GLP1R | MAOB 4093/4885TDP1 3907/4885L3MBTL1 3620/4885 |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABL1, MAP4K2, MAP4K5 | MAOB 628/4885TDP1 840/4885L3MBTL1 3987/4885 |
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, FFAR3 | MAOB 4234/4885TDP1 2943/4885L3MBTL1 2649/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | MAOB 659/4885TDP1 782/4885L3MBTL1 4181/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | MAOB 659/4885TDP1 782/4885L3MBTL1 4181/4885 |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | ALOX5, ALOX15B, ALOX15 | MAOB 182/4885TDP1 2840/4885L3MBTL1 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.